Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.62Last Year’s EPS
-0.59Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -8.11%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment, driven by significant advancements in clinical trials, regulatory progress, and a strong financial position, despite increased expenses and ongoing net losses.Company Guidance
During the Kura Oncology Q4 2024 Financial Results Conference Call, the company provided guidance on several key metrics and milestones for its ziftomenib program. Kura plans to submit its first New Drug Application (NDA) for ziftomenib in Q2 2025, targeting relapsed/refractory NPM1-mutant Acute Myeloid Leukemia (AML). The company is preparing for the commercial launch of ziftomenib, expecting it to be a leading menin inhibitor in this market. Kura has aligned with both the U.S. FDA and the European Medicines Agency on pathways for accelerated approval of ziftomenib in frontline AML. Top-line results for the MRD-negative CR accelerated endpoint in intensive chemotherapy settings are anticipated in 2028. Financially, Kura ended 2024 with $727.4 million in cash, bolstered by a $330 million upfront payment from its Kyowa Kirin partnership, which will support their ziftomenib AML program through commercialization in the U.S. frontline setting. The company also achieved a net loss of $19.2 million in Q4 2024, an improvement from the $42.8 million loss in the same quarter of 2023.Positive Top-Line Results from KOMET-001
The Phase 2 registration-directed trial of ziftomenib in patients with relapsed/refractory NPM1-mutant AML achieved its primary endpoint, consistent with a targeted 20% to 30% CR/CRh rate, and the safety profile was consistent with prior reports.
Regulatory Progress for Ziftomenib
Alignment with FDA and EMA on potential pathways for accelerated approval in the US and Europe for ziftomenib in frontline AML, with plans for NDA submission in Q2 2025.
Strong Financial Position
Cash, cash equivalents, and short-term investments of $727.4 million as of December 31, 2024, expected to fund operations into 2027.
Collaboration Revenue Boost
Collaboration revenue from Kyowa Kirin partnership was $53.9 million for Q4 2024, compared to none in the corresponding quarter of 2023.
Future Prospects in Diabetes
Plans to nominate a next-generation menin inhibitor development candidate for use in diabetes in mid-2025, based on promising preclinical data.
---
KURA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KURA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $7.77 | $7.65 | -1.54% |
| Nov 07, 2024 | $17.77 | $17.68 | -0.51% |
| Aug 08, 2024 | $19.12 | $18.97 | -0.78% |
| May 02, 2024 | $20.59 | $20.63 | +0.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kura Oncology (KURA) report earnings?
Kura Oncology (KURA) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Kura Oncology (KURA) earnings time?
Kura Oncology (KURA) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KURA EPS forecast?
KURA EPS forecast for the fiscal quarter 2025 (Q1) is -0.62.
---